April 14, 2021 – Imbed Biosciences is proud to announce that its animal health product, MicroLyte® Vet, is now available in Canada through McCarthy and Sons Service.
McCarthy & Sons Service is a full-service veterinary marketing, supply, and distribution company. Their team of distribution representatives are well versed in surgical and wound care products, and has experience bringing innovative products to the animal health market in Canada. McCarthy has a sales team covering all of Canada as well as marketing support from their headquarters in Edmonton, Alberta.
The distribution was established as an extension of Imbed’s exclusive North America distribution partnership with Jorgensen Laboratories. Western Drug Distribution Center, also located in Edmonton, Alberta, is handling the import and warehousing of MicroLyte® Vet.
Canada has a significant veterinary market, with over 8 million dogs and over 8 million cats owned by approximately 41% of all households. Like Europe, regulatory steps have been taken in Canada to address antimicrobial resistance due to the overuse of antibiotics. MicroLyte® Vet is seen by veterinarians as an alternative that can be used to prevent infections while not running the risk of producing antibiotic-resistant strains.
Supported by an established animal health distribution company, Imbed Biosciences expects MicroLyte® Vet to quickly become a standard in Canada as it is now becoming across the United States. The CEO of Imbed Biosciences, Ankit Agarwal said, “Canada is a great opportunity for growth in our veterinary product line, and an important part of strengthening our animal health partnerships in North America.”
About Imbed Biosciences, Inc.
Imbed is a privately held biotech company registered with the FDA as a medical device manufacturer with an ISO 13485 certified quality management system. The company has a portfolio of products in development based on its patented Microlyte® Matrix technology for tissue engineering to combat local pain and infections in complex wounds such as burns, chronic ulcers, surgical wounds, epidermolysis bullosa, and colorectal surgeries. The research is funded in part by a Small Business Innovation Research grant #5R44AR061913 from the National Institute of Arthritis and Musculoskeletal and Skin Diseases.